Kinetics of SARS-CoV-2 Shedding in Nursing Home Residents and Staff
- PMID: 40317518
- PMCID: PMC12303745
- DOI: 10.1111/jgs.19499
Kinetics of SARS-CoV-2 Shedding in Nursing Home Residents and Staff
Abstract
Background: Nursing homes (NHs) were disproportionately affected by the COVID-19 pandemic. However, little is known regarding the kinetics of SARS-CoV-2 shedding in NH residents and staff, which could inform treatment and infection prevention.
Methods: We enrolled NH residents and staff in eight US states from April to November 2023 and analyzed the kinetics of SARS-CoV-2 using serial antigen and molecular (RT-PCR) tests, whole genome sequencing, and viral culture (VC). Symptoms, vaccination, and treatment were collected via interviews and chart review. Viral load trajectories were modeled with gamma distribution functional forms. Antigen and VC test positivity over time were assessed using a Chi-squared test.
Results: Of the 587 enrolled participants, 86 tested positive and 73 underwent testing for ≥ 10 days; most residents (78%) and staff (87%) had ≥ 3 COVID-19 vaccine doses. The modeled SARS-CoV-2 proliferation period (period prior to reaching peak viral load) had ended for 48% (14/29) of residents and 56% (9/16) of staff when they took the initial RT-PCR test. Both antigen and VC showed higher positivity rates early in the course of disease (Days 0-5 vs. Days ≥ 6) (antigen: p < 0·001, VC: p < 0·001). VC positivity was 15% after Day 5 (14/96); two participants were VC positive after Day 10.
Conclusions: Peak viral load occurs early in the disease, suggesting asymptomatic and presymptomatic transmission may be a significant driver of transmission. Only two participants had a positive VC after Day 10, supporting current isolation and return to work recommendations.
Keywords: COVID‐19; SARS‐CoV‐2; kinetics; nursing home; shedding.
Published 2025. This article is a U.S. Government work and is in the public domain in the USA. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
Conflict of interest statement
Conflicts of Interest
Stefan Gravenstein: Consulting or honoraria (Genentech, GSK, Icosavax, Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi, and Seqirus) and investigator-initiated and collaborative grants (Genentech, GSK, Moderna, Pfizer, Sanofi, and Seqirus).
Jennifer Meddings: Research funding: Dr. Meddings’s research has recently been supported by the Agency for Healthcare Research and Quality, the VA National Center for Patient Safety, and subcontract with Abt Global for research funded by the Centers for Disease Prevention and Control. Dr. Meddings’s research has recently been supported by contracts with the Health Research & Education Trust (HRET) involving the prevention of CAUTI, funded by AHRQ and the Centers for Disease Prevention and Control, and the Centers for Medicare and Medicaid Services. Dr. Meddings was also a recipient of the 2009–2015 National Institutes of Health (NIH) Clinical Loan Repayment Program. Employment: She is a salaried employee of the University of Michigan and the Ann Arbor VA Medical Center. Disclosures: Dr. Meddings has reported receiving honoraria from hospitals and professional societies devoted to complication prevention for lectures and teaching related to prevention and value-based purchasing policies involving catheter-associated urinary tract infection and hospital-acquired pressure ulcers. Dr. Meddings also serves as an Associated Editor for the
Figures
References
-
- Centers for Medicare & Medicaid Services, “COVID-19 Nursing Home Data,” accessed July 11, 2024, https://data.cms.gov/covid-19/covid-19-nursing-home-data.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
